BIRB 796

Product Description

BIRB 796 is a high affinity and selective p38 kinase inhibitor (K_d = 50-100 pM). Exhibits no significant inhibition on a panel of related kinases. Inhibits LPS-induced TNFα production in human PBMCs and whole blood (IC₅₀ values are 21 and 960 nM, respectively). Also inhibits JNK2α2 and c-Raf-1 (IC₅₀ values are 98 nM and 1.4 μM, respectively). BIRB 796 can be used in protocols for the chemical reprogramming of somatic cells to iPSCs. Cell permeable.

Solubility

Preparing Stock Solutions for BIRB 796

The following data is based on the product molecular weight 527.66

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	18.95 mL	94.76 mL	189.52 mL
0.5 mM	3.79 mL	18.95 mL	37.90 mL
1 mM	1.90 mL	9.48 mL	18.95 mL
5 mM	0.38 mL	1.90 mL	3.79 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Guan Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature 2022 PMID: 35418683
• Kuma BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J.Biol.Chem. 2005 PMID: 15755732
• Regan Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796). J.Med.Chem. 2003 PMID: 14561087
• Goldstein Selective p38α inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J.Med.Chem. 2010 PMID: 19950901
• Laufer Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region. J.Med.Chem. 2008 PMID: 18578517